Chronic diseases

Purpose and goal

There is a need for more competent capital within life science, with the resources, expertise and ability to link the innovation chain from research and early projects to commercialization and profitable companies in life science. Larger volumes of competent capital are also crucial to attracting international private capital and investors as well as fruitful collaborations with industrial players within and outside Sweden. The goal has therefore been to develop a strategy to increase the availability of competent capital to early life science companies.

Expected results and effects

The project has delivered a proposal for collaboration between public and private venture capital. The proposal was designed as a model for collaboration between public and private venture capital and was submitted to the governmental investigation on public risk capital. The project has also explored different opportunities for Swelife to stimulate the forming of a new VC fund within life science together with VC companies, Saminvest and other stakeholders. However, the proposed initiatives has proved difficult to implement within Vinnova’s assignment.

Planned approach and implementation

The project has involved a large number of stakeholders, both representing small companies, VC companies, funding agencies and support organisations.